融资与资金需求 - 公司于2024年5月22日完成公开发行,募集资金总额170万美元,扣除承销费用和发行费用后的净额约为140万美元[93] - 公司预计目前的30万美元现金不足以支持未来12个月的运营费用和资本支出,需要在未来6个月内筹集更多资金以维持持续经营和推进产品候选药物的临床开发[95] - 公司计划通过公开或私募股权发行、债务融资、合作和许可安排或其他融资方式筹集更多资金以继续推进产品候选药物的临床开发[96] - 如果公司通过发行股票筹集资金,股东将面临股权稀释[96] - 公司无法保证能够获得必要的额外资金支持其运营,如果获得这些资金,也无法保证足以满足公司的需求,因此存在持续经营的重大不确定性[96] 现金流情况 - 2024年上半年,公司经营活动产生的现金净流出为170万美元,主要由于净亏损230万美元,部分被经营资产和负债变动的300万美元净变化所抵消[99][100] - 2024年上半年,公司筹资活动产生的现金净流入为145.2万美元,主要来自2024年5月的公开发行[101] - 2024年上半年,公司现金及现金等价物净减少29.7万美元[98] 专利与合规 - 公司于2024年3月宣布发布IMC-2的全球专利,涵盖对长COVID的抗病毒治疗,这将有助于简化在全球范围内获得专利保护的过程[81] - 公司于2024年5月收到纳斯达克通知,公司普通股未能符合1美元最低出价要求,公司已申请听证会并获得延期至2024年10月28日前达到合规要求[86,87] 战略合作 - 公司继续探索通过战略合作伙伴关系、合作或其他交易来创造股东价值的补充机会[82]

长COVID治疗研究进展 - 完成了BHC-202 3组对照研究的入组，比较两种剂量的valacyclovir/celecoxib组合与安慰剂在12周内治疗长COVID症状[4] - 正在进行BHC-202研究的盲法安全性分析，结果显示研究药物(valacyclovir和celecoxib组合或匹配安慰剂)至今耐受性良好，未报告严重不良事件，仅有少数短暂的治疗期不良事件[5] - 最近一项发表在《新英格兰医学杂志》的研究显示,长COVID后遗症仍然是一个重大的未满足医疗需求,未接种疫苗的患者在急性感染后发展长COVID的可能性是接种疫苗者的两倍以上[8] - 公司的主要研发候选药物IMC-1(famciclovir和celecoxib的固定剂量组合)已获得FDA的快速通道认定[13] 公司财务状况 - 公司完成了1.7百万美元的公开发行,将运营资金延长至2025年第一季度[6] - 第二季度研发费用为33.6万美元,较2023年同期下降了39.7%[9] - 第二季度管理费用为73.4万美元,较2023年同期下降了20.2%[10] - 第二季度净亏损为104.9万美元,每股基本和稀释亏损为0.05美元,较2023年同期的140.9万美元和0.08美元有所改善[11] - 截至2024年6月30日,公司现金余额为302.0万美元,预计可为运营提供资金支持至2025年第一季度[12] 公司发展策略 - 公司继续积极探索通过战略合作伙伴关系、合作或其他交易来增加股东价值的机会[7]

- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center’s Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiv ...

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage b ...

ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (Nasdaq: VIRI) is a development-stage ...

- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms - ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic d ...

- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms - ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39811 Virios Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4314201 (S ...

Exhibit 99.1 Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, Ga., May 9, 2024 -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-39811 VIRIOS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 85-4314201 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. ...